Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).

Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).

Abstract: The present disclosure relates to a novel high-low temperature radiator for internal combustion engine engineering machinery, which is provided with a water inlet pipe, a water inlet chamber, a radiator core body, a water outlet chamber, a water separation plate and a water outlet pipe which are sequentially communicated, the water inlet pipe is communicated with the water inlet chamber, and the water inlet chamber is communicated with the radiator core body; the radiator core body is divided into two parts: a radiator low-temperature core body and a radiator high-temperature core body; the water outlet chamber is divided into two parts: a low-temperature water outlet chamber and a high-temperature water outlet chamber, and the water outlet pipe is divided into a low-temperature water outlet pipe and a high-temperature water outlet pipe according to the core body and the water chamber from which the cooling liquid flows.

Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?v?3 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).

Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?v?3 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).

Abstract: The present disclosure relates to a novel high-low temperature radiator for internal combustion engine engineering machinery, which is provided with a water inlet pipe, a water inlet chamber, a radiator core body, a water outlet chamber, a water separation plate and a water outlet pipe which are sequentially communicated, the water inlet pipe is communicated with the water inlet chamber, and the water inlet chamber is communicated with the radiator core body; the radiator core body is divided into two parts: a radiator low-temperature core body and a radiator high-temperature core body; the water outlet chamber is divided into two parts: a low-temperature water outlet chamber and a high-temperature water outlet chamber, and the water outlet pipe is divided into a low-temperature water outlet pipe and a high-temperature water outlet pipe according to the core body and the water chamber from which the cooling liquid flows.

Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?v?3 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).

Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).

Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).

Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).

Abstract: A combination therapy is provided and is directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. The compositions and methods include a combined administration of VLO4 and VP12 (ECL12).

Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).

Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an a5?1 antagonist with an a2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).

Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?v?3 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12).

Abstract: The present invention provides a layered structure including a fullerene layer exhibiting Ohmic behavior. The layered device includes a layer of fullerenes and a layer of a fluoride compound of pre-selected thickness. The layered structure includes a third layer of an electrically conductive material located on the second layer to which electrical contact can be made. The thickness of the second layer is selected so that the layered structure exhibits substantially Ohmic contact across the first, second and third layers. The present invention also provides a light-emitting device which includes a substrate and a first electrically conductive layer defining an anode electrode layer on the substrate. The device includes an electron transport layer which includes fullerenes, and a second electrically conductive layer defining a cathode electrode layer on the electron transport layer. The device includes a layer of light-emissive material between the anode electrode layer and the electron transport layer.

Abstract: The present invention provides a top-emission organic light emitting diode hybrid with a layer of fullerene as electron transport layer. The structure of top-emission OLED is either conventional or inverted, which includes two electrodes, a hole injection layer (HIL); a hole transport layer (HTL); an electron transport layer (ETL) including a layer of fullerene; an emissive layer, which is sandwiched between HTL and ETL. The fullerene layer functions as charge transport to reduce driving voltages.

Abstract: The invention provides three-coordinated organoboron compounds that are useful for photoluminescence and electroluminescence. Compounds of the invention include light emitters, preferably emitting intense blue light, electron transporters, hole transporters and hole injectors. A particularly preferred such compound is p-(1-naphthylphenylamino)-4,4?-biphenyldimesitylborane (BNPB), which demonstrates all of these properties. The invention further provides methods of synthesizing such three-coordinated boron compounds, methods of producing photoluminescence and electroluminescence, methods for charge transports, methods for hole injection, methods of applying the compounds in thin films, and uses of the compounds of the invention in luminescent probes, and electroluminescent displays.

Abstract: The present invention provides an organic light-emitting device (OLED) is comprised of: (a) a cathode for external negative bias lead; (b) an anode for external positive bias lead; (c) an embedded charge injection electrode (ECIE) between the aforementioned cathode and anode; (d) an active region emitting light between the cathode and the anode. The ECIE is selected from low work function elements including Ca, Mg, Al, Ag, Au, Ni, Fe, Ni, and Co, bilayers including Fluorides/Al, Mg/Ag, Ca/Al, and trilayers of Fluorides/Al/Fluorides, Fluorides/Al/(Ca, Mg). The light-emitting layer is elected from conjugated small organic molecules and polymers. The anode is selected based from known high work function materials including ITO, SnO2, Ni, Pt, Au, p++ semiconductors (c-Si, a-Si, a-Si:H, poly silicon). The cathode is selected from one or more layers of high electrical conductive metals and alloys such as ITO, Al, Cr, Cu, Ag, Au, Ni, Fe, Ni, W, Mo and Co.

Abstract: The present invention provides a layered structure including a fullerene layer exhibiting Ohmic behavior. The layered device includes a layer of fullerenes and a layer of a fluoride compound of pre-selected thickness. The layered structure includes a third layer of an electrically conductive material located on the second layer to which electrical contact can be made. The thickness of the second layer is selected so that the layered structure exhibits substantially Ohmic contact across the first, second and third layers. The present invention also provides a light-emitting device which includes a substrate and a first electrically conductive layer defining an anode electrode layer on the substrate. The device includes an electron transport layer which includes fullerenes, and a second electrically conductive layer defining a cathode electrode layer on the electron transport layer. The device includes a layer of light-emissive material between the anode electrode layer and the electron transport layer.